DAVENPORT 13F: Adds $27M to Danaher (DHR) Stake

According to a Form 13F filed with the SEC on October 14, 2026, Davenport increased its investment in Danaher Corporation (NYSE:DHR). Note that 13F filings are backward-looking and reflect holdings as of the end of the reported period, meaning they may not represent the investor's current position today.

What Changed in Davenport's Danaher Position

Davenport lifted its stake in Danaher by adding 122,935 shares during the quarter. That marked an 18.1% increase, bringing its total ownership to 801,278 shares. The reported value of the position stood at about $178.4 million at the time of the filing.

Other Institutional Activity in Danaher Corporation

Blackrock Inc. grew its holdings by 3,444,403 shares, ending with 55,084,630 shares worth about $12.6 billion. Vanguard Capital Management LLC grew its holdings by 250,870 shares, finishing with 41,377,076 shares valued at roughly $9.5 billion. FMR, LLC grew its holdings by 7,006,075 shares, closing out the period with 29,540,895 shares worth $6.8 billion. State Street Corporation grew its holdings by 560,696 shares, ending with 28,456,019 shares valued at $6.5 billion. Wellington Management Group, LLP rounded out the group by adding 1,542,446 shares to hold 16,316,834 shares worth approximately $3.7 billion.

Danaher Corporation Stock Up 1.8%

Danaher shares recently traded around $228.70 as of October 16, 2026, sitting about 5.8% below their 52-week high of $242.80. The stock trades above its 50-day moving average of $213.32 and its 200-day moving average of $201.33.

Recent Earnings

Danaher generated trailing twelve-month revenue of $25.1 billion and earnings of $5.61 per share. The company reported a net profit margin of 15.9% and a return on equity of 7.6%. Investors should watch the upcoming earnings report on October 21, 2026, to gauge whether business trends are holding steady.

Dividend

Danaher pays an annual dividend yield of 0.69%, backed by a dividend payout ratio of 25.7%.

Insider Buying and Selling at Danaher Corporation

Insider transactions included a sale of 1,358 shares by Director Alan G Spoon on May 1, 2026, at a price of $174.67 for a total value of $237,207. Chief Executive Officer Rainer M Blair also sold 58,255 shares on August 21, 2026, valued at $12.7 million.

Analysts Set New Price Targets

Analysts set new price targets in October 2026. Guggenheim maintained its Buy rating while lifting its price target from $200.00 to $250.00 on October 1. RBC Capital kept an Outperform rating with a $250 target on October 5, while Barclays maintained an Overweight rating with a $255 target on October 7. Morgan Stanley and TD Cowen both maintained their positive views on October 13, setting targets of $240 and $255 respectively. Across the street, the stock carries a strong buy recommendation and a mean target price of $244.14 from 22 analysts.

About Danaher Corporation

Danaher Corporation operates as a global science and technology innovator. The firm creates professional, medical, industrial, and research products, focusing heavily on diagnostics, life sciences, and biotechnology solutions to help solve complex medical challenges.

Bottom Line

Institutional interest in Danaher remains active as the healthcare firm heads into its next earnings report on October 21, 2026. Because 13F reports reflect past quarters, observers should monitor subsequent filings to see how major funds adjust their positions next.